DC to vote on rep-licensing bill

Let's see your license. That's what Washington, DC docs might be saying to pharma reps next year if the district council approves a measure regulating drug makers' sales people tomorrow. The SafeRx Act is a hot topic in Big Pharma land, of course; if D.C. requires reps to be licensed, states might follow suit. And the measure also wouldn't let pharma companies use doctors' prescription data for marketing purposes without the doctors' knowledge.

Council member David Catania, who introduced the potential rules, says pharma reps can mislead physicians and patients into buying costly new drugs rather than cheaper brand names or even cheaper generics; sometimes, he says, they even pretend to be medical professionals when they're not. Other professions are licensed, he argues: "If it is good enough for cosmetologists, it ought to be good enough for the pharmaceutical company."

Drug makers aren't keen on the plan, of course. They say the rules would overlap with federal law, and are therefore unnecessary. Meanwhile, they're already suing the states of New Hampshire, Maine, and Vermont over rules against the sort of doctor-oriented data-mining the DC measure would regulate.

- take a look at this article from the Washington Post

Related Articles:
Dr. Drug Rep tells all. Report
Top Lilly exec plays secret sales agent. Report
No freebies? No entry for pharma reps. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity